GlassScriptPhysician profile
Jason C Graff
NPI 1316973100
$8,139.96
in general payments reported to CMS, 2019-2025
25 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,500 · 2020: $1,497 · 2022: $55.47 · 2023: $1,401 · 2024: $2,044 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,939 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,938.77 |
| Education | $148.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $2,500.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $2,091.40 | 2023-2025 | Fasenra, Tezspire, Breztri |
| Harmony Biosciences LLC | $1,668.32 | 2020-2024 | Wakix |
| Electromed, INC. | $283.49 | 2023-2025 | Smartvest |
| Glaxosmithkline, LLC. | $190.38 | 2023-2025 | Nucala, Trelegy Ellipta, Shingrix |
| United Therapeutics Corporation | $160.85 | 2023-2025 | Tyvaso, Tyvaso |
| Axsome Therapeutics, INC. | $156.17 | 2022-2025 | Sunosi |
| Genzyme Corporation | $155.19 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.55 | 2023-2025 | Ofev |
| Mylan Specialty L.P. | $128.58 | 2023-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $96.89 | 2023-2024 | Eliquis |
| Resmed Corp | $93.40 | 2024 | |
| Jazz Pharmaceuticals INC. | $89.32 | 2023-2024 | |
| Inspire Medical Systems, INC. | $51.00 | 2023-2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $42.63 | 2024-2025 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $42.19 | 2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Viatris Specialty LLC | $39.71 | 2025 | Yupelri |
| Philips North America LLC | $37.15 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Grifols USA, LLC | $34.82 | 2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $30.60 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $23.03 | 2025 | Xolair |
| Avadel Cns Pharmaceuticals, LLC | $18.83 | 2024 | Lumryz |
| Amgen INC. | $18.37 | 2024 | Tezspire |
| 3b Medical, INC. | $17.91 | 2025 | Luna |
| Merck Sharp & Dohme LLC | $16.18 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Graff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.